Prurigo Nodularis market to exhibit growth at a CAGR of 23.2% (2020-2034), driven by strong uptake of DUPIXENT, recent approval of NEMLUVIO, promising JAK and OX40 inhibitors in the Pipeline, along ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback